ProShares Ultra Nasdaq Biotechnology (BIB)

57.76
Delayed Data
As of 4:00pm ET
 -0.18 / -0.31%
Today’s Change
44.62
Today|||52-Week Range
69.62
+3.01%
Year-to-Date

Investment Objective

The investment seeks daily investment results that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index-. The fund invests in securities and derivatives that ProShare Advisors believes- in combination- should have similar daily return characteristics as two times (2x) the daily return of the index. The index is a modified capitalization weighted index that includes securities of NASDAQ listed companies that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark ("ICB") which also meet other eligibility criteria determined by NASDAQ. The fund is non-diversified.

3 ETFs to Watch on Biotech Earnings
Feb 10 / Zacks.com - Paid Partner Content
 

Performance

1 month-5.91% 3 years-8.76%
3 months+11.40% 5 years+29.19%
1 year+18.70% Since inception+29.67%
Data through 02/21/2018

Quote Details

Previous close$57.94
Open day’s range57.76 – 60.11
Net asset value (NAV)57.96 (02/20/2018)
Daily volume113,764
Average volume (3 months)249,853
Data as of 4:00pm ET, 02/21/2018

Peer Comparisonvs. Trading--leveraged equity ETFs

 BIBCategory
Performance 5-yr return+29.19%+16.48%
Expense Gross exp ratio1.04%2.01%
Risk 5 year sharpe ratio0.84--
Net assets$449.4M$103.7M
Average market cap$16.9B--
Average P/E----
Dividend / Share--0.31%

Competitors

PPLC Portfolio+ S&P 500® ETF
SPLX UBS ETRACS Monthly Reset 2xLeveraged S&P...
SPUU Direxion Daily S&P 500® Bull 2X Shares

Holdings

Top 5 Sectors
Portfolio weighting
Business service --
Consumer goods --
Consumer service --
Energy --
Financial service --
Top 10 Holdings
Portfolio weighting
-- 23.67%
-- 20.38%
-- 19.02%
-- 18.53%
-- 16.32%
-- 7.87%
GILD Gilead Sciences6.83%
BIIB Biogen6.58%
AMGN Amgen6.45%
CELG Celgene6.11%